

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Kohshi UENO et al. Conf.:
Appl. No.: NEW Group: Unassigned
Filed: March 10, 2004 Examiner: UNASSIGNED
For: CERTAIN 1,3-DISUBSTITUTED INSOQUINOLINE
DERIVATIVES (AS AMENDED)

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 10, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, Applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).
09/852,850
09/509,778

U.S. Filing Date(s)
May 11, 2001
March 31, 2000

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.


Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 

John W. Bailey, #32,881

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000


JWB/RG/bsh
0425-1114P

Attachment(s) : ☒ PTO-1449(s)

☐ References

☐ Foreign Search Report

☐ Other:

(Rev. 02/12/2004)

[illegible][illegible]

	Chemical Abstract DN 94:174912, also cited as NL 8002113
	Chemical Abstract Dn 85:160167, also cited as FR 2268524
	Chemical Abstract Dn 69:35972, also cited as CH 438308
	Nair M.D., Chemical Abstract DN 77:164414, also cited as Indian J. Chem. 10/4, 337-40 (1972)

RG
JWB/RG/bsh